🇺🇸 Levodopa / Carbidopa in United States
1,563 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 1,563
Most-reported reactions
- Dyskinesia — 241 reports (15.42%)
- Fall — 220 reports (14.08%)
- Drug Ineffective — 154 reports (9.85%)
- Hallucination — 153 reports (9.79%)
- Parkinson^S Disease — 149 reports (9.53%)
- Gait Disturbance — 141 reports (9.02%)
- On And Off Phenomenon — 131 reports (8.38%)
- Fatigue — 129 reports (8.25%)
- Tremor — 127 reports (8.13%)
- Dizziness — 118 reports (7.55%)
Other Neurology approved in United States
Frequently asked questions
Is Levodopa / Carbidopa approved in United States?
Levodopa / Carbidopa does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Levodopa / Carbidopa in United States?
Ross D. Zafonte, MD is the originator. The local marketing authorisation holder may differ — check the official source linked above.